Is Dengue Vaccine Protection Possible?

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Four dengue virus serotypes (DENVs) cause mild illness and severe vascular permeability syndrome in tropical regions.
• DENVs' unique antigenic and biological characteristics impede vaccine development.
• Existing tetravalent dengue vaccine candidates face challenges in efficacy and safety, particularly in seronegative populations.

Purpose of the Study:

• To review the progress and challenges in developing tetravalent dengue vaccines.
• To evaluate the performance of candidate vaccines in clinical trials.
• To identify key factors for achieving balanced and sustained protective immunity against DENVs.

Main Methods:

• Review of phase 3 clinical trial data for three tetravalent candidate dengue vaccines.
• Analysis of vaccine efficacy and safety profiles, including protection against different DENV serotypes and risk of severe dengue.
• Assessment of immune responses elicited by candidate vaccines.

Main Results:

• Dengvaxia partially protects seropositive individuals but increases severe dengue risk in some seronegatives.
• TAK-003 shows protection against DENV-2 but limited efficacy against other DENV serotypes.
• A novel NIH vaccine demonstrated protection against DENV-2 and DENV-3 challenge in seronegative adults.

Conclusions:

• Current tetravalent dengue vaccine candidates exhibit variable efficacy and safety concerns.
• Achieving balanced and sustained immunity against all four DENV serotypes may require nearly whole DENV genomes.
• Further research is needed to develop safe and effective dengue vaccines for diverse populations.